RLMD

MKT CAP:$525M

Relmada Therapeutics, Inc.

Market Cap

$525M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.14+$2.77 (+63.39%)

Apr 21, 2026

Company Details

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadon...

CEO

Sergio Traversa

IPO Date

Jun 20, 2014

Website

www.relmada.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$56M

EPS (Diluted)

-$1.80

Free Cash Flow

-$40M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 11, 2026

PENDING

Q3 2025

Nov 13, 2025

$0EPS -$0.30

Q2 2025

Aug 7, 2025

$0EPS -$0.30

Q1 2025

May 12, 2025

$0EPS -$0.58

FY 2024

Mar 27, 2025

$0EPS -$2.65

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$34M
Q1 22	$0	$0	-$38M
Q2 22	$0	$0	-$46M
Q3 22	$0	$0	-$39M
Q4 22	$0	$0	-$39M
Q1 23	$0	$0	-$28M
Q2 23	$0	$0	-$26M
Q3 23	$0	$0	-$23M
Q4 23	$0	$0	-$27M
Q1 24	$0	$0	-$23M
Q2 24	$0	$0	-$19M
Q3 24	$0	$0	-$23M
Q4 24	$0	$0	-$19M
Q1 25	$0	$0	-$18M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	-$10M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$38M	-$38M
Q1 22	-$19M	-$19M
Q2 22	-$22M	-$22M
Q3 22	-$27M	-$27M
Q4 22	-$36M	-$36M
Q1 23	-$17M	-$17M
Q2 23	-$13M	-$13M
Q3 23	-$12M	-$12M
Q4 23	-$10M	-$10M
Q1 24	-$13M	-$13M
Q2 24	-$13M	-$13M
Q3 24	-$17M	-$17M
Q4 24	-$9M	-$9M
Q1 25	-$18M	-$18M
Q2 25	-$6M	-$6M
Q3 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$4
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+63.4%
Q1 22	—	+70.9%
Q2 22	—	+72.0%
Q3 22	—	-9.2%
Q4 22	—	+13.2%
Q1 23	—	-26.5%
Q2 23	—	-42.8%
Q3 23	—	-41.4%
Q4 23	—	-30.7%
Q1 24	—	-18.3%
Q2 24	—	-27.7%
Q3 24	—	+1.4%
Q4 24	—	-28.9%
Q1 25	—	-20.7%
Q2 25	—	-45.7%
Q3 25	—	-55.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$18M	—
Q1 22	$12M	—
Q2 22	$12M	—
Q3 22	$8M	—
Q4 22	$12M	—
Q1 23	$11M	—
Q2 23	$11M	—
Q3 23	$11M	—
Q4 23	$10M	—
Q1 24	$8M	—
Q2 24	$7M	—
Q3 24	$8M	—
Q4 24	$7M	—
Q1 25	$4M	—
Q2 25	$3M	—
Q3 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 21	$25M	$9M	—
Q1 22	$25M	$13M	—
Q2 22	$31M	$15M	—
Q3 22	$31M	$8M	—
Q4 22	$27M	$12M	—
Q1 23	$16M	$12M	—
Q2 23	$14M	$12M	—
Q3 23	$10M	$12M	—
Q4 23	$15M	$12M	—
Q1 24	$13M	$10M	—
Q2 24	$11M	$8M	—
Q3 24	$11M	$12M	—
Q4 24	$11M	$8M	—
Q1 25	$12M	$6M	—
Q2 25	$3M	$7M	—
Q3 25	$4M	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$45M	$176M	$221M
Q2 22	$37M	$175M	$212M
Q3 22	$43M	$142M	$184M
Q4 22	$5M	$143M	$148M
Q1 23	$29M	$104M	$132M
Q2 23	$14M	$104M	$119M
Q3 23	$7M	$100M	$106M
Q4 23	$4M	$92M	$96M
Q1 24	$1M	$82M	$84M
Q2 24	$2M	$68M	$70M
Q3 24	$1M	$53M	$54M
Q4 24	$4M	$41M	$45M
Q1 25	$1M	$26M	$27M
Q2 25	$1M	$19M	$21M
Q3 25	$1M	$13M	$14M
Q4 25	$3M	$90M	$93M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	19M	+9.2%	+17.3%
Q1 22	28M	+48.8%	+71.3%
Q2 22	30M	+5.4%	+75.5%
Q3 22	30M	+0.4%	+72.0%
Q4 22	30M	+0.1%	+57.7%
Q1 23	30M	0.0%	+6.0%
Q2 23	30M	0.0%	+0.5%
Q3 23	30M	0.0%	+0.1%
Q4 23	30M	0.0%	0.0%
Q1 24	30M	+0.1%	+0.1%
Q2 24	30M	+0.1%	+0.2%
Q3 24	30M	0.0%	+0.2%
Q4 24	30M	0.0%	+0.2%
Q1 25	30M	+0.8%	+0.9%
Q2 25	33M	+9.2%	+10.0%
Q3 25	33M	0.0%	+10.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	10
Q1 22	$0	10
Q2 22	$0	10
Q3 22	$0	10
Q4 22	$0	14
Q1 23	$0	14
Q2 23	$0	14
Q3 23	$0	14
Q4 23	$0	20
Q1 24	$0	20
Q2 24	$0	20
Q3 24	$0	20
Q4 24	$0	17
Q1 25	$0	17
Q2 25	$0	17
Q3 25	$0	17

Revenue / Employee